News

Intra-Cellular Therapies Boosts CAPLYTA Sales Forecast for 2024

Intra-Cellular Therapies Boosts CAPLYTA Sales Forecast for 2024

Strong Financial Performance in Q3 2024

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) reported robust financial results for the third quarter of 2024, showcasing a remarkable year-over-year increase in sales. CAPLYTA's net product sales reached $175.2 million, a significant jump from $125.8 million during the same quarter in 2023, indicating a 39% growth. This achievement reflects the growing acceptance and use of CAPLYTA among healthcare providers.

CAPLYTA Prescription Growth Continues

Alongside the sales boost, CAPLYTA demonstrated a 38% increase in total prescriptions compared to the previous year. This upward trend highlights the ongoing demand for CAPLYTA, positioning the product favorably within the competitive landscape of treatments for psychiatric disorders.

Raised Sales Guidance for 2024

In response to the favorable market conditions and increasing demand, Intra-Cellular Therapies has raised its CAPLYTA sales guidance range for the full year of 2024. The company now anticipates net product sales between $665 million and $685 million, up from prior estimates. This revised outlook is indicative of the positive trajectory the company expects to maintain.

Regulatory Advances for Lumateperone

The company recently held a successful pre-supplemental NDA (sNDA) meeting with the U.S. Food and Drug Administration (FDA). The submission for lumateperone as an adjunctive treatment for major depressive disorder (MDD) is anticipated within the fourth quarter of 2024. This submission is poised to open new avenues for revenue generation and further solidify Intra-Cellular's role in the mental health sector.

Continued Clinical Developments

Intra-Cellular is also advancing its clinical pipeline with ongoing studies for ITI-1284. These studies target generalized anxiety disorder (GAD), agitation, and psychosis linked to Alzheimer’s disease. The company aims to provide innovative solutions for these complex conditions, enhancing the quality of life for many patients.

Commercial Growth Strategies

To capitalize on the expanding market for CAPLYTA, Intra-Cellular has strategically increased its sales force, adding approximately 150 representatives to better engage with primary care physicians. This expansion highlights the company's commitment to ensuring that CAPLYTA reaches a broad audience of patients who could benefit from this treatment.

Financial Highlights of Q3

  • Total revenues for Q3 2024 stood at $175.4 million, compared to $126.2 million in Q3 2023.
  • The net loss for this quarter was $26.3 million, a slight increase from the $24.3 million loss reported during the same period last year.
  • Cash reserves, including cash equivalents and investment securities, totaled an impressive $1 billion, affording the company significant resources to support ongoing and future projects.

Looking Ahead

Intra-Cellular Therapies is keenly focused on leveraging its financial and strategic strengths to enhance its market presence. The robust performance in Q3, coupled with an optimistic sales outlook for CAPLYTA, positions the company for substantial growth as it navigates the competitive biopharmaceutical landscape.

Frequently Asked Questions

What are the key financial results for Intra-Cellular Therapies in Q3 2024?

The company reported net product sales of $175.2 million, a 39% increase from the previous year, with total revenues reaching $175.4 million.

How have CAPLYTA prescriptions changed?

CAPLYTA total prescriptions increased by 38% compared to the same period in 2023, showcasing its growing acceptance and demand in the market.

What is the revised sales guidance for CAPLYTA for 2024?

Intra-Cellular has raised its sales guidance for CAPLYTA to between $665 million and $685 million for the full year of 2024.

What regulatory advancements are anticipated for lumateperone?

The company expects to submit its sNDA for lumateperone for MDD treatment in Q4 2024 following a successful meeting with the FDA.

What initiatives is Intra-Cellular undertaking for commercial growth?

Intra-Cellular has expanded its sales force by adding around 150 representatives to enhance outreach and engagement with healthcare providers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 0

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 0

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 0

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 0

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 0

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 0

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 5

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 0

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Cybersecurity Excellence with CEH Hall of Fame 2025

Updated Category News Views 360

EC-Council Unveils Significant Findings on Ethical Hacking In a notable development for the cybersecurity field, EC-Council has recently presented the CEH Hall of Fame 2025 Industry Report, a comprehensive analysis that reveals how the Certified Ethical Hacker (CEH) certification is reshaping careers and enhancing national security. This data-focused report showcases the...

Continue Reading
CNN Implements $3.99 Monthly Paywall for Exclusive Content

Updated Category News Views 117

CNN Introduces Monthly Subscription for Premium Access CNN has recently announced a new paywall model for some users, requiring a monthly subscription of $3.99 for access to its online content. This pivotal decision marks CNN's strategic movement toward generating reliable digital revenue. A Shift Towards Subscription Models This initiative comes at a time when various...

Continue Reading
Maximizing Retirement Income: Smart Strategies for Couples

Updated Category News Views 306

Managing Income in Retirement: An Overview As retirees, many face the challenge of living on a limited nest egg, especially if their savings are modest. To navigate this, mastering the art of financial management in retirement becomes incredibly important. While Social Security provides a vital safety net for many, thorough planning and smart financial strategies can help...

Continue Reading
Growing Market for Paint Protection Film Expected to Thrive

Updated Category News Views 232

Introduction to the Paint Protection Film Market Austin—The paint protection film (PPF) market is witnessing remarkable growth, with projections indicating a valuation of USD 894.80 million within the next decade. This robust expansion, expected to develop at a compound annual growth rate (CAGR) of 6.01%, highlights the increasing priority consumers place on vehicle...

Continue Reading
Ericsson's Annual Report Highlights for Future Growth in Tech

Updated Category News Views 152

Ericsson's Annual Report Insights Ericsson, a leader in technology and communication innovations, has officially submitted its Annual Report on Form 20-F to the U.S. Securities and Exchange Commission (SEC). This report covers the company's operational performance and future strategies, reflecting its dedication to advancing mobile communication and connectivity...

Continue Reading